The Role of CBX5 in Head and Neck Cancer Cell Phenotypic Expression

Kegan Main OMS-2  
*Marian University - Indianapolis*

John Zemkewicz  
*Marian University - Indianapolis*

Colleen L. Doci Ph.D  
*Marian University - Indianapolis*

Follow this and additional works at: [https://mushare.marian.edu/mucom_rd](https://mushare.marian.edu/mucom_rd)

Part of the [Medicine and Health Sciences Commons](https://mushare.marian.edu/mucom_rd)

**Recommended Citation**
[https://mushare.marian.edu/mucom_rd/170](https://mushare.marian.edu/mucom_rd/170)

This Poster is brought to you for free and open access by the College of Osteopathic Medicine at MUShare. It has been accepted for inclusion in MU-COM Research Day by an authorized administrator of MUShare. For more information, please contact emandity@marian.edu.
• Head and neck squamous cell carcinomas (HNSCCs) have remained one of the common and lethal cancers around the world.
• HNSCC rapidly spread via the lymphatics system, leading to a higher percentage of initial late-stage diagnoses and poor prognoses for patients.
• CBX5 is downregulated highly metastatic breast cancers and may repress metastatic phenotypes.
• It is unclear what role is may have in HNSCC, or which specific functions of CBX5 drive its antimetastatic role.
• We aim to map molecular changes to phenotypic expression in order to provide better diagnostic prognoses for different HNSCC cell types as well as possible pharmacologic targets for treatment.

The Role of CBX5 in Head and Neck Cancer Cell Phenotypic Expression

Kegan Main, John Zemkewicz and Dr. Colleen L. Doci, Ph.D.
1 College of Osteopathic Medicine, Marian University Indianapolis
2 College of Health Sciences, Marian University Indianapolis

SUMMARY

- Head and neck squamous cell carcinomas (HNSCCs) have remained one of the common and lethal cancers around the world.
- HNSCC rapidly spread via the lymphatics system, leading to a higher percentage of initial late-stage diagnoses and poor prognoses for patients.
- CBX5 is downregulated highly metastatic breast cancers and may repress metastatic phenotypes.
- It is unclear what role CBX5 may have in HNSCC, or which specific functions of CBX5 drive its antimetastatic role.

HYPOTHESIS: Heterochromatin binding by CBX5, but not dimerization or ligand activation, is necessary to suppress in vitro metastasis in HNSCC cell lines.

CBX5 IS DOWNREGULATED IN AGGRESSIVE HNSCC

CBX5 GATEWAY CLONING

INTRODUCTION OF CBX5 POINT MUTATIONS

Figure 1. HNSCC rates are on the decline overall as are many cancers, however, the survivability of HNSCC has not significantly changed over time unlike other cancer subtypes.

Figure 2. Comparison of angiolymphatic invasion between N0- and N0+ patients. The clinical significance suggests that the genes that control the vascularity of tumors may be the strongest candidates for biomarker diagnosis in primary HNSCC tumors.

Figure 3. CD31 staining of blood vessels of HNSCC primary tumors in mice, which helped determine which HNSCC metastatic cell lines were vascular and avascular.

Figure 4. The CAL27 and UMSCC17B cell lines are metastatic vascular and appear to have lower constitutive expression of CBX5 than the HN12, and HR6 lines which are metastatic avascular.

Figure 5. Induction of the V22M point mutation interrupts CBX5’s ability to recognize the heterochromatin and bind to it. V22M-1 also had an additional unplanned mutation resulting in a frameshift and resultant total knockdown of CBX5 expression which fortuitously can be used as a negative control.

Figure 6. After early restriction digests showed a failed attempt to introduce I165E mutations we proceeded to only clone our V22M and W174A mutants to send for sequencing. In a preliminary restriction digest all 4 V22M mutants had correct lengths, and three W174A mutants were the correct length. These 7 were then sent for genetic sequencing to verify the correct mutations were present.

ACKNOWLEDGEMENTS

We would like to thank the Marian University and the MU College of Osteopathic Medicine for this opportunity and research equipment.